Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Factors That Govern the Induction of Long-Lived Antibody Responses.

Chackerian B, Peabody DS.

Viruses. 2020 Jan 7;12(1). pii: E74. doi: 10.3390/v12010074. Review.

2.

Self-Antigens Displayed on Liposomal Nanoparticles above a Threshold of Epitope Density Elicit Class-Switched Autoreactive Antibodies Independent of T Cell Help.

Chen Z, Wholey WY, Hassani Najafabadi A, Moon JJ, Grigorova I, Chackerian B, Cheng W.

J Immunol. 2020 Jan 15;204(2):335-347. doi: 10.4049/jimmunol.1801677. Epub 2019 Dec 13.

PMID:
31836655
3.

Assessing Antibody Specificity in Human Serum Using Deep Sequence-Coupled Biopanning.

Frietze KM, Core SB, Linville A, Chackerian B, Peabody DS.

Methods Mol Biol. 2020;2070:157-171. doi: 10.1007/978-1-4939-9853-1_9.

PMID:
31625095
4.

Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Sangesland M, Ronsard L, Kazer SW, Bals J, Boyoglu-Barnum S, Yousif AS, Barnes R, Feldman J, Quirindongo-Crespo M, McTamney PM, Rohrer D, Lonberg N, Chackerian B, Graham BS, Kanekiyo M, Shalek AK, Lingwood D.

Immunity. 2019 Oct 15;51(4):735-749.e8. doi: 10.1016/j.immuni.2019.09.001. Epub 2019 Sep 25.

PMID:
31563464
5.

Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy.

Maphis NM, Peabody J, Crossey E, Jiang S, Jamaleddin Ahmad FA, Alvarez M, Mansoor SK, Yaney A, Yang Y, Sillerud LO, Wilson CM, Selwyn R, Brigman JL, Cannon JL, Peabody DS, Chackerian B, Bhaskar K.

NPJ Vaccines. 2019 Jun 3;4:26. doi: 10.1038/s41541-019-0118-4. eCollection 2019. Erratum in: NPJ Vaccines. 2019 Aug 13;4:36.

6.

A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine.

Janitzek CM, Peabody J, Thrane S, H R Carlsen P, G Theander T, Salanti A, Chackerian B, A Nielsen M, Sander AF.

Sci Rep. 2019 Mar 27;9(1):5260. doi: 10.1038/s41598-019-41522-5.

7.

Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9.

Kunda NK, Peabody J, Zhai L, Price DN, Chackerian B, Tumban E, Muttil P.

Hum Vaccin Immunother. 2019;15(7-8):1995-2002. doi: 10.1080/21645515.2019.1593727. Epub 2019 Apr 19.

PMID:
30883270
8.

Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.

Frietze KM, Lijek R, Chackerian B.

Expert Rev Vaccines. 2018 Nov;17(11):959-966. doi: 10.1080/14760584.2018.1534587. Epub 2018 Oct 20.

9.

Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a.

Ntumngia FB, Thomson-Luque R, Galusic S, Frato G, Frischmann S, Peabody DS, Chackerian B, Ferreira MU, King CL, Adams JH.

J Infect Dis. 2018 Aug 24;218(7):1110-1118. doi: 10.1093/infdis/jiy273.

10.

A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.

Zhai L, Peabody J, Pang YS, Schiller J, Chackerian B, Tumban E.

Antiviral Res. 2017 Nov;147:116-123. doi: 10.1016/j.antiviral.2017.09.012. Epub 2017 Sep 20.

11.

Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses.

Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee WK, Pasqualini R, Arap W.

EMBO Mol Med. 2017 Oct;9(10):1327-1330. doi: 10.15252/emmm.201708072. No abstract available.

12.

Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature.

Peabody J, Muttil P, Chackerian B, Tumban E.

Papillomavirus Res. 2017 Jun;3:116-120. doi: 10.1016/j.pvr.2017.03.004. Epub 2017 Apr 8.

13.

VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation.

Daly SM, Joyner JA, Triplett KD, Elmore BO, Pokhrel S, Frietze KM, Peabody DS, Chackerian B, Hall PR.

Sci Rep. 2017 Apr 4;7(1):637. doi: 10.1038/s41598-017-00753-0.

14.

Pathogen-specific deep sequence-coupled biopanning: A method for surveying human antibody responses.

Frietze KM, Pascale JM, Moreno B, Chackerian B, Peabody DS.

PLoS One. 2017 Feb 2;12(2):e0171511. doi: 10.1371/journal.pone.0171511. eCollection 2017.

15.

Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.

Chackerian B, Remaley A.

Curr Opin Lipidol. 2016 Aug;27(4):345-50. doi: 10.1097/MOL.0000000000000312. Review.

PMID:
27389630
16.

Engineering virus-like particles as vaccine platforms.

Frietze KM, Peabody DS, Chackerian B.

Curr Opin Virol. 2016 Jun;18:44-9. doi: 10.1016/j.coviro.2016.03.001. Epub 2016 Mar 29. Review.

17.

Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.

Saboo S, Tumban E, Peabody J, Wafula D, Peabody DS, Chackerian B, Muttil P.

Mol Pharm. 2016 May 2;13(5):1646-55. doi: 10.1021/acs.molpharmaceut.6b00072. Epub 2016 Apr 11.

18.

Moving towards a new class of vaccines for non-infectious chronic diseases.

Chackerian B, Frietze KM.

Expert Rev Vaccines. 2016 May;15(5):561-3. doi: 10.1586/14760584.2016.1159136. Epub 2016 Mar 16. No abstract available.

PMID:
26919571
19.

Progress and prospects for L2-based human papillomavirus vaccines.

Jiang RT, Schellenbacher C, Chackerian B, Roden RB.

Expert Rev Vaccines. 2016 Jul;15(7):853-62. doi: 10.1586/14760584.2016.1157479. Epub 2016 Mar 10. Review.

20.

Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.

Frietze KM, Roden RB, Lee JH, Shi Y, Peabody DS, Chackerian B.

Cancer Immunol Res. 2016 Feb;4(2):157-64. doi: 10.1158/2326-6066.CIR-15-0165. Epub 2015 Nov 20.

21.

Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle Platform.

Caldeira J, Bustos J, Peabody J, Chackerian B, Peabody DS.

PLoS One. 2015 Oct 30;10(10):e0141407. doi: 10.1371/journal.pone.0141407. eCollection 2015.

22.

A cholesterol-lowering VLP vaccine that targets PCSK9.

Crossey E, Amar MJA, Sampson M, Peabody J, Schiller JT, Chackerian B, Remaley AT.

Vaccine. 2015 Oct 26;33(43):5747-5755. doi: 10.1016/j.vaccine.2015.09.044. Epub 2015 Sep 26.

23.

Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.

Crossey E, Frietze K, Narum DL, Peabody DS, Chackerian B.

PLoS One. 2015 Jul 6;10(7):e0132560. doi: 10.1371/journal.pone.0132560. eCollection 2015.

24.

Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.

Tumban E, Muttil P, Escobar CA, Peabody J, Wafula D, Peabody DS, Chackerian B.

Vaccine. 2015 Jun 26;33(29):3346-53. doi: 10.1016/j.vaccine.2015.05.016. Epub 2015 May 21.

25.

Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.

O'Rourke JP, Peabody DS, Chackerian B.

Curr Opin Virol. 2015 Apr;11:76-82. doi: 10.1016/j.coviro.2015.03.005. Epub 2015 Mar 29. Review.

26.

Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway.

O'Rourke JP, Daly SM, Triplett KD, Peabody D, Chackerian B, Hall PR.

PLoS One. 2014 Nov 7;9(11):e111198. doi: 10.1371/journal.pone.0111198. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0118160.

27.

A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.

Ord RL, Caldeira JC, Rodriguez M, Noe A, Chackerian B, Peabody DS, Gutierrez G, Lobo CA.

Malar J. 2014 Aug 18;13:326. doi: 10.1186/1475-2875-13-326.

28.

Why HIV virions have low numbers of envelope spikes: implications for vaccine development.

Schiller J, Chackerian B.

PLoS Pathog. 2014 Aug 7;10(8):e1004254. doi: 10.1371/journal.ppat.1004254. eCollection 2014 Aug. Review. No abstract available.

29.

Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Tyler M, Tumban E, Dziduszko A, Ozbun MA, Peabody DS, Chackerian B.

Vaccine. 2014 Jul 23;32(34):4267-74. doi: 10.1016/j.vaccine.2014.06.054. Epub 2014 Jun 21.

30.

The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.

Tyler M, Tumban E, Peabody DS, Chackerian B.

Biotechnol Bioeng. 2014 Dec;111(12):2398-406. doi: 10.1002/bit.25311. Epub 2014 Jul 31.

31.

Targeted immunomodulation using antigen-conjugated nanoparticles.

McCarthy DP, Hunter ZN, Chackerian B, Shea LD, Miller SD.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 May-Jun;6(3):298-315. doi: 10.1002/wnan.1263. Epub 2014 Mar 10. Review.

32.

Second-generation prophylactic HPV vaccines: successes and challenges.

Tyler M, Tumban E, Chackerian B.

Expert Rev Vaccines. 2014 Feb;13(2):247-55. doi: 10.1586/14760584.2014.865523. Epub 2013 Dec 18. Review.

33.

A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.

Van Rompay KK, Hunter Z, Jayashankar K, Peabody J, Montefiori D, LaBranche CC, Keele BF, Jensen K, Abel K, Chackerian B.

J Virol. 2014 Feb;88(4):2011-24. doi: 10.1128/JVI.02447-13. Epub 2013 Dec 4.

34.

A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.

Tumban E, Peabody J, Peabody DS, Chackerian B.

Vaccine. 2013 Sep 23;31(41):4647-54. doi: 10.1016/j.vaccine.2013.07.052. Epub 2013 Aug 9.

35.

VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.

Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B.

PLoS One. 2012;7(11):e49751. doi: 10.1371/journal.pone.0049751. Epub 2012 Nov 19.

36.

Delivery of ricin toxin a-chain by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.

Epler K, Padilla D, Phillips G, Crowder P, Castillo R, Wilkinson D, Wilkinson B, Burgard C, Kalinich R, Townson J, Chackerian B, Willman C, Peabody D, Wharton W, Brinker CJ, Ashley C, Carnes E.

Adv Healthc Mater. 2012 May;1(3):348-53. doi: 10.1002/adhm.201200022. Epub 2012 Apr 2.

37.

Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.

Ashley CE, Carnes EC, Epler KE, Padilla DP, Phillips GK, Castillo RE, Wilkinson DC, Wilkinson BS, Burgard CA, Kalinich RM, Townson JL, Chackerian B, Willman CL, Peabody DS, Wharton W, Brinker CJ.

ACS Nano. 2012 Mar 27;6(3):2174-88. doi: 10.1021/nn204102q. Epub 2012 Feb 14.

38.

Genital delivery of virus-like particle and pseudovirus-based vaccines.

Cuburu N, Chackerian B.

Expert Rev Vaccines. 2011 Sep;10(9):1245-8. doi: 10.1586/erv.11.104. No abstract available.

39.

A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.

Tumban E, Peabody J, Peabody DS, Chackerian B.

PLoS One. 2011;6(8):e23310. doi: 10.1371/journal.pone.0023310. Epub 2011 Aug 17.

40.

Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.

Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, Padilla DP, Phillips B, Carter MB, Willman CL, Brinker CJ, Caldeira Jdo C, Chackerian B, Wharton W, Peabody DS.

ACS Nano. 2011 Jul 26;5(7):5729-45. doi: 10.1021/nn201397z. Epub 2011 Jun 7.

41.

Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.

Hunter Z, Tumban E, Dziduszko A, Chackerian B.

Vaccine. 2011 Jun 20;29(28):4584-92. doi: 10.1016/j.vaccine.2011.04.051. Epub 2011 May 5.

42.

Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles.

Chackerian B, Caldeira Jdo C, Peabody J, Peabody DS.

J Mol Biol. 2011 Jun 3;409(2):225-37. doi: 10.1016/j.jmb.2011.03.072. Epub 2011 Apr 9.

43.

The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers.

Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, Hanna TN, Liu J, Phillips B, Carter MB, Carroll NJ, Jiang X, Dunphy DR, Willman CL, Petsev DN, Evans DG, Parikh AN, Chackerian B, Wharton W, Peabody DS, Brinker CJ.

Nat Mater. 2011 May;10(5):389-97. doi: 10.1038/nmat2992. Epub 2011 Apr 17. Erratum in: Nat Mater. 2011 Jun;10(6):476.

44.

Virus-like particle based vaccines for Alzheimer disease.

Chackerian B.

Hum Vaccin. 2010 Nov;6(11):926-30. doi: 10.4161/hv.7.1.12655. Epub 2010 Nov 1. Review.

PMID:
20864801
45.

Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, Chackerian B, Peabody DS.

Vaccine. 2010 Jun 17;28(27):4384-93. doi: 10.1016/j.vaccine.2010.04.049. Epub 2010 Apr 29.

46.

Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant.

Li QY, Gordon MN, Chackerian B, Alamed J, Ugen KE, Morgan D.

J Neuroimmune Pharmacol. 2010 Mar;5(1):133-42. doi: 10.1007/s11481-009-9183-1.

PMID:
20066498
47.

Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Hunter Z, Smyth HD, Durfee P, Chackerian B.

Vaccine. 2009 Dec 11;28(2):403-14. doi: 10.1016/j.vaccine.2009.10.035. Epub 2009 Oct 20.

48.

Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.

Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo Caldeira J, Chackerian B.

J Mol Biol. 2008 Jun 27;380(1):252-63. doi: 10.1016/j.jmb.2008.04.049. Epub 2008 Apr 27.

49.
50.

Virus-like particles: flexible platforms for vaccine development.

Chackerian B.

Expert Rev Vaccines. 2007 Jun;6(3):381-90. Review.

PMID:
17542753

Supplemental Content

Loading ...
Support Center